Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Uncover which cash back cards come with no annual fee. Choose the best option for your spending habits!
27,852 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
In a hypothetical mid-June scenario, SpaceX launches a historic $1.75 trillion IPO, raising $85.7 billion and closing...
Barclays has boosted its Ionis target to $106, signaling a roughly 46% upside from recent levels as olezarsen eyes pe...
SpaceX used its soaring stock to fund a $60 billion Cursor acquisition in stock, turning a fresh IPO into a powerful ...
Unity Software’s latest guidance sparked a sharp rally, underscoring how Vector AI could redefine monetization in int...
When a company's CFO sells a chunk of shares, investors want to know what it means. This guide explains the implicati...
MP Materials is catching investor attention again in 2026 as policy support, domestic production efforts, and a risin...
Argan stock ascended today as investors cheered stronger profits and a brighter outlook for energy infrastructure tie...
Tesla sits at a fair-value crossroads in 2026, with capex and AI initiatives guiding a modest upside. Here’s how inve...
Apple is taking a guarded AI route, leaning on partnerships and modest capex. The strategy could alter AI investing d...
Fastenal is delivering steady, long‑term gains through an embedded, service‑driven model. Here’s why the stock fits a...
In 2026, Nvidia stock has cooled from its sky-high run. If you own NVDA, you’ll want a clear plan: trim profits, reba...